|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Dow AgroSciences LLC (DOW) Achieves World's First Registration For Plant-Made Vaccines
1/31/2006 1:49:20 PM
Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, (NYSE: DOW), announced today that it has received the world's first regulatory approval for a plant-made vaccine from the United States Department of Agriculture (USDA) Center for Veterinary Biologics. This approval represents an innovative milestone for the company and the industry.
"With this achievement Dow AgroSciences is revolutionizing the field of preventative medicine with plant-cell-produced vaccines," said Butch Mercer, Dow AgroSciences' global business leader for Animal Health.
The Dow AgroSciences ConcertTM Plant-Cell-Produced System represents a new category of plant-made vaccines. This leading edge technology utilizes plant cells instead of whole plants in a secure, bio-contained environment to produce vaccines. Because of this bio-contained production system, concerns and challenges associated with making vaccines in whole plants or food crops are eliminated.
"Being the first company to ever register a plant-made vaccine is another example of Dow AgroSciences' cutting edge approach to bringing highly novel and differentiated solutions to the market," said Jerome Peribere, Dow AgroSciences' president and CEO.
The ConcertTM Plant-Cell-Produced System uses only the necessary parts of the disease causing agent to stimulate immunity in a manufacturing process that is totally free of animal components. According to John Cuffe, Dow AgroSciences' R&D leader for Animal Health, "This approval is a perfect example of how biotechnology is advancing science by creating a new category of vaccines that is both safe and effective."
By achieving this regulatory milestone, Dow AgroSciences has demonstrated that this new technology fits within the existing USDA Center for Veterinary Biologics regulatory approval process. Dow AgroSciences can now focus its efforts on developing new, innovative vaccines with an emphasis on animal health. Possible target animals include: horses, companion animals (such as dogs and cats), poultry, swine, and cattle. Furthermore, utilizing this revolutionary technology for human diseases is a real possibility.
This milestone achievement by Dow AgroSciences was the result of effective collaborations with prominent organizations and institutions including Washington University, Boyce Thompson Institute for Plant Research, Benchmark Biolabs, Inc., and The Biodesign Institute at Arizona State University. In less than five years Dow AgroSciences moved the science forward, established a production facility, and received this regulatory approval.
|
|
|
|
|
|
|
|
|
|
|